Science 278, 1626C1629 [PubMed] [Google Scholar] 5. to mouse CD1d have become valuable tools in elucidating the mechanism of antigen loading and presentation. Here, we report the 3.1 ? resolution crystal structure of the Fab of one of these antibodies, L363, bound to mCD1d complexed with the GalCer analog C20:2, revealing that L363 is an iNKT TCR-like antibody that binds CD1d-presented GalCer in a manner similar to the TCR. The structure reveals that Mouse monoclonal to HK1 L363 depends on both the L and H chains for binding to the glycolipid-mCD1d complex, although only the L chain is involved in contacts with the glycolipid antigen. The H chain of L363 features residue Trp-104, which mimics the TCR CDR3 residue Leu-99, which is crucial for CD1d binding. We characterized the antigen-specificity of L363 toward several different glycolipids, demonstrating that whereas the TCR can induce structural changes in both antigen and CD1d to recognize disparate lipid antigens, the antibody L363 can only induce the F roof formation in CD1d but fails to reorient the glycolipid headgroup necessary for binding. In summary, L363 is a powerful tool to study mechanism of iNKT cell activation for structural analogs of KRN7000, and our study can aid in the design of antibodies with altered antigen specificity. Keywords: Antibodies, Antigen Presentation, Glycolipids, Immunology, T Cell, CD1d, TCR-like Antibody Introduction Type I or semi-invariant natural killer T (iNKT)3 cells are a population of T lymphocytes that express both markers of natural killer cells and T cells. Because iNKT cells rapidly produce cytokines after antigen encounter (within 2C4 h), they have been termed innate-like Wnt/β-catenin agonist 1 immune cells, or cells that bridge the innate and adaptive immune system (1). iNKT cells express Wnt/β-catenin agonist 1 a semi-invariant T cell receptor (TCR) that recognizes glycolipid antigens (Ag) presented by the nonclassical MHC class I-like molecule CD1d (2). NKT cells are characterized by expression of a conserved TCR chain rearrangement (V14J18 in mouse and V24J18 in humans) that pairs predominantly with the TCR chain V8.2 (also to a smaller extend V7 and Vb2), whereas in human beings the most frequent mixture is V24V11 (1, 3). The prototypical antigen -galactosylceramide (GalCer, KRN7000) continues to be identified inside a display for anti-B16 melanoma substances and is thoroughly studied like a powerful iNKT Ag due to its powerful and fast activation of iNKT cells resulting in the creation of both pro (Th1) and anti-inflammatory (Th2) cytokines (4). Due to the opposing ramifications of Th2 and Th1 cytokines, artificial KRN7000 analogs have already been created to skew the cytokine response to the Th1- or Th2-biased phenotype, which is more encouraging in controlling the condition progression in a variety of animal models. For instance, the glycolipids OCH, PBS-25, and C20:2 had been found out to induce Th2-biased cytokine creation (5C7), which is effective for the control of Wnt/β-catenin agonist 1 Th1-powered autoimmune diseases, whereas NU-GalCer and -C-GalCer had been found out to stimulate Th1-biased cytokine creation, leading to excellent antitumor response weighed against KRN7000, most likely through improved transactivation of organic killer cells (8, 9). The system resulting in the induction of Th1- or Th2-biased reactions by changing the glycolipid antigen framework happens to be under intense analysis and takes benefit of some recently created mCD1d-KRN7000 particular antibodies. The antibodies have already been elevated against mCD1d-KRN7000 complexes and don’t bind to unloaded mCD1d or mCD1d that is packed with the self-antigen iGb3 (7). The antibodies understand many structural analogs of KRN7000 also, including -C-GalCer and OCH, making them valuable tools to review differences in presentation of Th2 and Th1.